Sanofi-Aventis’ CEO Pipeline: R&D Chief Le Fur Tapped To Succeed Dehecq
Executive Summary
Incoming Sanofi-Aventis CEO Gerard Le Fur will bring considerable research and development experience to the helm of the French drug maker
You may also be interested in...
Sanofi CEO succession finalized
Sanofi-Aventis' Board of Directors formally appoints Gerard Le Fur to succeed Jean-Francois DeHecq as the firm's CEO, effective Jan. 1, during a Dec. 14 meeting; DeHecq will remain board chairman. Le Fur, who currently serves as senior exec VP-science and medical affairs, was nominated for the post in May (1"The Pink Sheet" June 5, 2006, p. 11)...
Sanofi CEO succession finalized
Sanofi-Aventis' Board of Directors formally appoints Gerard Le Fur to succeed Jean-Francois DeHecq as the firm's CEO, effective Jan. 1, during a Dec. 14 meeting; DeHecq will remain board chairman. Le Fur, who currently serves as senior exec VP-science and medical affairs, was nominated for the post in May (1"The Pink Sheet" June 5, 2006, p. 11)...
Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?
As Bristol-Myers Squibb prepares to weather patent losses for its two top-selling products - Pravachol and Plavix - the firm is sticking by a conservative approach to research & development